Pre-β-HDL formation relates to high-normal free thyroxine in type 2 diabetes mellitus

Clinical Biochemistry

Volumn 49, Issue 1, 2016, Pages 41-46

  van Tienhoven Wind, Lynnda J N ^a   Perton, Frank G ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

High density lipoproteins; Phospholipid transfer protein; Pre HDL; Thyroid function; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; FREE THYROXINE INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; PATHOPHYSIOLOGY; THYROID FUNCTION TEST;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; MALE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROXINE;

EID: 84952988976     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.08.024     Document Type: Article

References (35)

1. Taylor P.N., Razvi S., Pearce S.H., Dayan C.M. Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J. Clin. Endocrinol. Metab. 2013, 98:3562-3571.
2. van Tienhoven-Wind L.J., Dullaart R.P.F. Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients 2015, 7:1352-1377.
3. Walsh J.P. Setpoints and susceptibility: do small differences in thyroid function really matter?. Clin. Endocrinol. 2011, 75:158-159.
4. Dullaart R.P.F., de Vries R., Roozendaal C., Kobold A.C., Sluiter W.J. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. Clin. Endocrinol. 2007, 67:668-673.
5. Takamura N., Akilzhanova A., Hayashida N., Kadota K., Yamasaki H., Usa T., Nakazato M., et al. Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 2009, 204:e77-e81.
6. Asvold B.O., Bjøro T., Platou C., Vatten L.J. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin. Endocrinol. 2012, 77:911-917.
7. Rosenson R.S., Brewer H.B., Chapman M.J., Fazio S., Hussain M.M., Kontush A., Krauss R.M., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57:392-410.
8. Triolo M., Annema W., Dullaart R.P.F., Tietge U.J. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark. Med 2013, 7:457-472.
9. de Vries R., Borggreve S.E., Dullaart R.P.F. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin. Lab. 2003, 49:601-613.
10. Rye K.A., Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 2004, 24:421-428.
11. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., Fuster V., Goldstein J., Hellerstein M., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919.
12. Hattori H., Kujiraoka T., Egashira T., Saito E., Fujioka T., Takahashi S., Ito M., et al. Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. Clin. Chem. 2004, 50:589-595.
13. Asztalos B.F., Cupples L.A., Demissie S., Horvath K.V., Cox C.E., Batista M.C., Schaefer E.J. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2181-2187.
14. Sethi A.A., Sampson M., Warnick R., Muniz N., Vaisman B., Nordestgaard B.G., Tybjaerg-Hansen A., et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin. Chem. 2010, 56:1128-1137.
15. Hirayama S., Miida T., Miyazaki O., Aizawa Y. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007, 30:1289-1291.
16. de Vries R., Perton F.G., van Tol A., Dullaart R.P.F. Carotid intima media thickness is related positively to plasma pre ß-high density lipoproteins in non-diabetic subjects. Clin. Chim. Acta 2012, 413:473-477.
17. Kane J.P., Malloy M.J. Prebeta-1 HDL and coronary heart disease. Curr. Opin. Lipidol. 2012, 23:367-371.
18. Triolo M., Kwakernaak A.J., Perton F.G., de Vries R., Dallinga-Thie G.M., Dullaart R.P.F. Low normal thyroid function enhances plasma cholesteryl ester transfer in type 2 diabetes mellitus. Atherosclerosis 2013, 228:466-471.
19. Triolo M., de Boer J.F., Annema W., Kwakernaak A.J., Tietge U.J., Dullaart R.P.F. Low normal free T4 confers decreased high-density lipoprotein antioxidative functionality in the context of hyperglycaemia. Clin. Endocrinol. 2013, 79:416-423.
20. Dallinga-Thie G.M., van Tol A., Dullaart R.P.F., Atorvastatin D. lipid intervention (DALI) study group. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein. Biochim. Biophys. Acta 2009, 1791:714-718.
21. Selvin S. Statistical Analysis of Epidemiological Data 1996, Oxford University Press, New York.
22. van Tienhoven-Wind L., Dullaart R.P.F. Low normal thyroid function as a determinant of increased large very low density lipoprotein particles. Clin. Biochem. 2015, 48:489-494.
23. Dallinga-Thie G.M., Dullaart R.P., van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr. Opin. Lipidol. 2007, 18:251-257.
24. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., Pugh K., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
25. Ishida B.Y., Frolich J., Fielding C.J. Prebeta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. J. Lipid Res. 1987, 28:778-786.
26. Chétiveaux M., Lalanne F., Lambert G., Zair Y., Ouguerram K., Krempf M. Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. Eur. J. Clin. Invest. 2006, 36:29-34.
27. Miida T., Kawano M., Fielding C.J., Fielding P.E. Regulation of the concentration of pre beta high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry 1992, 31:11112-11117.
28. Asztalos B.F., Schaefer E.J., Horvath K.V., Yamashita S., Miller M., Franceschini G., Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res. 2007, 48:592-599.
29. Dullaart R.P.F., de Vries R., Kwakernaak A.J., Perton F., Dallinga-Thie G.M. Increased large VLDL particles confer elevated cholesteryl ester transfer in diabetes. Eur. J. Clin. Invest. 2015, 45:36-44.
30. Diekman M.J., Anghelescu N., Endert E., Bakker O., Wiersinga W.M. Changes in plasma low-density lipoprotein (LDL)- and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. J. Clin. Endocrinol. Metab. 2000, 85:1857-1862.
31. Wang F., Tan Y., Wang C., Zhang X., Zhao Y., Song X., Zhang B., et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J. Clin. Endocrinol. Metab. 2012, 97:2724-2731.
32. de Vries R., Kerstens M.N., Sluiter W.J., Groen A.K., van Tol A., Dullaart R.P.F. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005, 48:1105-1113.
33. Vigersky R.A., Filmore-Nassar A., Glass A.R. Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab. 2006, 91:225-227.
34. Díez J.J., Iglesias P. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin. Endocrinol. 2013, 78:505-511.
35. Lupoli R., Di Minno A., Tortora A., Ambrosino P., Lupoli G.A., Di Minno M.N. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J. Clin. Endocrinol. Metab. 2014, 99:E143-E148.